rs1553645164
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_004656.4(BAP1):c.1153C>T(p.Arg385*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,512 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. R385R) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_004656.4 stop_gained
Scores
Clinical Significance
Conservation
Publications
- BAP1-related tumor predisposition syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: ClinGen, Ambry Genetics, G2P, Orphanet, Genomics England PanelApp, Labcorp Genetics (formerly Invitae)
- Kury-Isidor syndromeInheritance: AD Classification: STRONG, MODERATE Submitted by: Ambry Genetics, G2P
- renal cell carcinomaInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| BAP1 | NM_004656.4 | c.1153C>T | p.Arg385* | stop_gained | Exon 12 of 17 | ENST00000460680.6 | NP_004647.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| BAP1 | ENST00000460680.6 | c.1153C>T | p.Arg385* | stop_gained | Exon 12 of 17 | 1 | NM_004656.4 | ENSP00000417132.1 | ||
| BAP1 | ENST00000296288.9 | c.1099C>T | p.Arg367* | stop_gained | Exon 12 of 17 | 5 | ENSP00000296288.5 | |||
| BAP1 | ENST00000490804.1 | n.581C>T | non_coding_transcript_exon_variant | Exon 2 of 3 | 2 | |||||
| BAP1 | ENST00000469613.5 | c.-75C>T | upstream_gene_variant | 1 | ENSP00000418320.1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461512Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 727064 show subpopulations
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
BAP1-related tumor predisposition syndrome Pathogenic:2
This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. -
This sequence change creates a premature translational stop signal (p.Arg385*) in the BAP1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BAP1 are known to be pathogenic (PMID: 21874000, 23684012). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with mesothelioma, cutaneous melanoma and/or uveal melanoma (PMID: 22545102, 25974357, 27181379). ClinVar contains an entry for this variant (Variation ID: 485271). For these reasons, this variant has been classified as Pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.R385* pathogenic mutation (also known as c.1153C>T), located in coding exon 12 of the BAP1 gene, results from a C to T substitution at nucleotide position 1153. This changes the amino acid from an arginine to a stop codon within coding exon 12. This mutation has been shown to segregate with disease in a family with several BAP1-associated tumors including cutaneous melanoma, ocular melanoma, and atypical melanocytic nevi (Njauw CN et al. PLoS ONE. 2012;7(4):e35295). The p.R385* mutation has also been reported in an individual diagnosed with a meningioma, multiple cutaneous melanomas, as well as meosothelioma (Betti M et al. Cancer Lett. 2016 08;378:120-30). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at